|
Oct 9
|
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Oct 9
|
UroGen Appoints Chris Degnan as Chief Financial Officer
|
|
Oct 3
|
UroGen begins subject dosing in Phase III bladder cancer drug trial
|
|
Oct 2
|
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Aug 29
|
UroGen Pharma to Present at Upcoming Investor Conferences
|
|
Aug 16
|
UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88
|
|
Jun 27
|
UroGen Pharma Stock Earns 91 RS Rating
|
|
Jun 18
|
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jun 17
|
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jun 17
|
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
|
|
Jun 13
|
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
|
|
Jun 13
|
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
|
|
May 14
|
UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
|
|
May 13
|
UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
|
|
May 13
|
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
|
|
May 12
|
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
|
|
May 7
|
UroGen Pharma to Participate at Upcoming Investor Conferences
|
|
May 5
|
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
|
|
May 4
|
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
|
|
May 4
|
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
|